Acute DiarrheaNCT02896465
Human Milk Oligosaccharides and Childhood Diarrhoea
A study testing Oral rehydration solution, Zinc and Human milk oligosaccharides in people with Acute Diarrhea, run by Société des Produits Nestlé (SPN) at 1 site in Bangladesh.
Trial summary
Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea. Read more about this study
- Who is it for?
- Ages 6 months to 2 years
- Conditions the study is for
- Acute Diarrhea
- What is being tested?
- Oral rehydration solution, Zinc and Human milk oligosaccharides
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 435 participants
- Where
- 1 siteBangladesh
- Study dates
- Jun 2016to Feb 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 2 years
- All sexes
- No healthy volunteers
- Child
Inclusion Criteria: Non breast-fed children (group I and group II):
- Both male and female children between the ages of 6 months to 2 years.
- Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
- Guardian is willing to have the child admitted to the hospital as an inpatient until resolution of diarrhea and to return to the clinic with the child on Day 14 after admission for a final evaluation.
- Written informed consent must be obtained prior to admission to this study.
- The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.
Exclusion Criteria: Non breast-fed children (group I and group II):
- Children of either sex who are fully or partially breast-fed until one week before enrolment (since breastfed children receive naturally HMO, their inclusion into the ORS/zinc or HMO/ORS/zinc arms would critically interfere with the study question; depending on children's age 30 to 50 % of mothers would do so at icddr,b). However, an unblinded reference group will be constituted by age-matched children who are breastfed at the moment of hospitalization for acute diarrhea and where the mothers want to continue breastfeeding on the study ward (so breastfeeding is only an exclusion for the randomized groups).
- Suspected or confirmed cholera as detected by a positive DF examination in stool collected on admission. (The large volume and quick evacuation of stool could interfere with product presence in the gut)
- Symptom duration > 48 hours at screening.
- Vomiting severity that is likely to make administration and retention of test product impossible.
- Severe malnutrition defined (using z-scores) as: severe stunting (SS; height-for-age z-score < -3.00); severe underweight (SU; weight-for-age z-score < -3.00), and severe wasting (SW; weight-for-height z-score < -3.00), using the World Health Organization reference value. Moderate malnutrition was defined as follows: moderate stunting (height-for-age z-score -3.00 to < -2.00); moderate underweight (weight-for-age z-score -3.00 to < -2.00); and moderate wasting (weight-for-height z-score -3.00 to < -2.00). We considered children as well-nourished if their z-scores for weight-for-age, height-for-age and weight-for-height z-score were form -2.00 to +1.00. Children with moderate malnutrition will be enrolled since they develop with higher frequency PD).
- Child already receiving antibiotics or anti-motility drugs for this diarrhea episode prior to screening.
- Children with any food allergy.
Breast-fed children, (Group III - Reference group)
- Exclusive Breastfed children Either sex: Male and female
- Age 6-12 month
- Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
- Written informed consent must be obtained prior to admission to this study.
- The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Treatment of Acute Childhood Diarrhoea With Human Milk Oligosaccharides and Impact on Gut Micro Biota Dysbiosis and Nutritional Status
Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea.
Read the detailed description
The trial is single site, double blind, randomized of HMO addition (1.5 g /day) to standard of care in paediatric diarrhoea patients. HMO application and follow-up of the children at home will be done for 2 weeks. Control patients receive only the standard of care (ORS plus zinc). A breastfed group of diarrhoea patients will serve as reference group.
The total sample size is 495 patients. Patients will be females and males aged 6 months to 2 years old with acute diarrhoea.
- Conditions
- Acute Diarrhea
- Being tested
- Oral rehydration solution, Zinc, Human milk oligosaccharides, Breastfeeding
- Keywords
- Children, Diarrhea, Human milk oligosaccharides
- Medical subject headings
- Diarrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral rehydration solutionOther
Also called ORS
ZincOther
Human milk oligosaccharidesOther
Also called HMO
BreastfeedingOther
| Study group | Role | What they receive |
|---|---|---|
| ORS+ZINC | Active comparator | Oral rehydration solution + Zinc Receives: Other: Oral rehydration solution; Other: Zinc |
| ORS+ZINC+HMO | Experimental | Oral rehydration solution + Zinc + Human milk oligosaccharides Receives: Other: Oral rehydration solution; Other: Zinc; Other: Human milk oligosaccharides |
| ORS+ZINC+Breastfeeding | Placebo comparator | Oral rehydration solution + Zinc + Breastfeeding Receives: Other: Oral rehydration solution; Other: Zinc; Other: Breastfeeding |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement (change) of clinical symptoms of diarrhea
Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods.
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Secondary outcomes (8)
Stools output
Stools output, expressed as g/kg of body weight (cumulative output)
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Weight gain
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Adverse events
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Daily stool frequency
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
The number of vomiting
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
The duration of vomiting
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Change in Z-score
Measured: Day1, Day14
The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input
Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2016 (estimated)
- Study startJun 2016
- Primary completionOct 2018
- Study completionFeb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute DiarrheaStudies of the same condition, open and under way.
- More trials run by Société des Produits Nestlé (SPN)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 435 participants (actual)
Sponsor and investigators
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02896465
- Sponsor's protocol ID
- 13.26.INF
- Status last verified
- Jul 2019
- First submitted
- 10 Aug 2016
- Last updated
- 23 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment of Acute Childhood Diarrhoea With Human Milk Oligosaccharides and Impact on Gut Micro Biota Dysbiosis and Nutritional Status
- ClinicalTrials.gov ID
- NCT02896465
- Acronym / sponsor ID
- 13.26.INF
- Conditions
- Acute Diarrhea
- Keywords
- Children, Diarrhea, Human milk oligosaccharides
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 435 participants (actual)
- Lead sponsor
- Société des Produits Nestlé (SPN)Industry (pharma, biotech, devices)
- Study start
- Jun 2016 (actual)
- Primary completion
- Oct 2018 (actual)
- Study completion
- Feb 2019 (actual)
- First posted
- 12 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea.
Detailed description
The trial is single site, double blind, randomized of HMO addition (1.5 g /day) to standard of care in paediatric diarrhoea patients. HMO application and follow-up of the children at home will be done for 2 weeks. Control patients receive only the standard of care (ORS plus zinc). A breastfed group of diarrhoea patients will serve as reference group.
The total sample size is 495 patients. Patients will be females and males aged 6 months to 2 years old with acute diarrhoea.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ORS+ZINC | Active comparator | Other: Oral rehydration solution, Other: ZincOral rehydration solution + Zinc |
| ORS+ZINC+HMO | Experimental | Other: Oral rehydration solution, Other: Zinc, Other: Human milk oligosaccharidesOral rehydration solution + Zinc + Human milk oligosaccharides |
| ORS+ZINC+Breastfeeding | Placebo comparator | Other: Oral rehydration solution, Other: Zinc, Other: BreastfeedingOral rehydration solution + Zinc + Breastfeeding |
Who may qualify
- Ages
- 6 months to 2 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral rehydration solutionAlso: ORS | Other | ORS+ZINC, ORS+ZINC+Breastfeeding, ORS+ZINC+HMO |
| Zinc | Other | ORS+ZINC, ORS+ZINC+Breastfeeding, ORS+ZINC+HMO |
| Human milk oligosaccharidesAlso: HMO | Other | ORS+ZINC+HMO |
| Breastfeeding | Other | ORS+ZINC+Breastfeeding |
Primary outcome
Improvement (change) of clinical symptoms of diarrhea
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods.
8 secondary outcomes
Stools output
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Weight gain
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Adverse events
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Daily stool frequency
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
The number of vomiting
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
The duration of vomiting
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Change in Z-score
Time frame: Day1, Day14
The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input
Time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2019.
- Individual participant dataSharing planned: No
Related trials for Acute Diarrhea
Not yet recruiting
Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months
Acute Watery Diarrhea, Acute Watery Diarrhoea
Enrolling by invitation
Hypernatremia Fluid Therapy in Childhood Diarrhoea
Hypernatremia, Acute Watery Diarrhea
Recruiting
Bacillus Clausii Versus Multistrain Probiotics for Acute Watery Diarrhea in Children
Acute Watery Diarrhea
Active, not recruiting
Comparison of Bacillus Clausii and Saccharomyces Boulardii for Acute Diarrhea at Day 3
Acute Watery Diarrhea
Not yet recruiting
Rural Water Filtration and Health Study
Diarrhea, Enteric Pathogens
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oral rehydration solution, Zinc and Human milk oligosaccharides in people with Acute Diarrhea, run by Société des Produits Nestlé (SPN) at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement (change) of clinical symptoms of diarrhea (time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2019; AzTrials last refreshed its copy on 7 Nov 2026.